SCHEMBL5689738

SCHEMBL5689738

OCC(CCNC1CCC(c2ccc(OCc3ccccc3)cc2)CC1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LIPG Q9Y5X9 1/20 0.47
FOXM1 Q08050 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.45
MAOA P21397 4/20 0.44
MAOB P27338 4/20 0.44
KDM1A O60341 4/20 0.44
PRKCA P17252 2/20 0.43
PRKCD Q05655 2/20 0.43
CYP2C9 P11712 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
KCNH2 Q12809 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5690102 1.00 KDM4E (0.47) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5689745 1.00 KDM4E (0.47) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5689751 1.00 KDM4E (0.47) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5690064 0.87 KDM4E (0.49) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5690073 0.87 KDM4E (0.49) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5690067 0.87 KDM4E (0.49) KDM4EKMT2ASMN1; SMN2LIPGFOXM1
SCHEMBL5690220 0.86 MRGPRX4 (0.44) KDM4EKMT2ASMN1; SMN2LIPGMRGPRX4
SCHEMBL5691602 0.85 SOS1 (0.43) SMN1; SMN2CYP2C9ALDH1A1
SCHEMBL5691598 0.85 SOS1 (0.43) SMN1; SMN2CYP2C9ALDH1A1
SCHEMBL5690088 0.81 FOXM1 (0.55) KDM4EKMT2ASMN1; SMN2LIPGFOXM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0982026-B1 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers HOFFMANN LA ROCHE (CH) 2006-05-17 EP disclosed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed